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The  monocyte  has  been  perceived  as  a  relatively  inactive  member  of the 
monocyte/macrophage series, i.e., a cell in transport to an anatomic site where 
differentiation to the macrophage will occur.  Modification of this perception is 
merited  in  light  of the  ready  capacity  of monocytes,  as  well  as  their  tissue- 
localized progeny, the elicited macrophage, to initiate and propagate coagulation 
protease  pathways (reviewed  in  references  1-4).  The  human monocyte given 
appropriate direct collaboration by bacterial lipopolysaccharide (LPS), 1 immune 
complex-stimulated T  lymphocytes (5-7), or a lymphokine (8, 9) from allogene- 
icaily or antigen-stimulated T  cells (10,  1 1), produces and expresses on its surface 
a  cell  membrane  lipoprotein,  i.e.,  tissue  factor,  the  initiating cofactor of the 
extrinsic coagulation protease pathway (12,  13).  This initiating event is attribut- 
able to the calcium-dependent binding of Factor VII or VIIa to tissue factor (14, 
15) to form a  molecular complex capable of efficiently converting the zymogen 
Factor  X  to  its active  form  by  virtue  of the  limited  proteolytic specificity of 
Factor VII and VIIa. This protease, the only coagulation protease that is proven 
to be active in the zymogen form (16),  also can proteolytically activate Factor 
IX, of the intrinsic pathway (17). 
In the human (18) and the mouse (19) an independent procoagulant protease, 
monocyte prothrombinase,  has been identified. This protease can directly me- 
diate the conversion of prothrombin to thrombin. Other studies have implicated 
additional cellular proteases including a  rabbit tumor cell-associated Factor X- 
activating cysteine protease (20),  a  Factor X-activating protease in  LPS-stimu- 
lated rabbit Kuppfer cells (21), a  vitamin K-dependent protease activity associ- 
ated with Lewis lung carcinoma (22),  and a  murine macrophage protease with 
Factor X-activating properties  (23),  We have implicated the synthesis of valid 
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Factor VII/VIIa by human peripheral blood mononuclear cells (PBM) following 
LPS stimulation (24). 
In the present study we demonstrate that appropriately induced human mon- 
ocytes can produce and assemble  Factor VII or VIIa in a  proteolytically active 
form on their surface in the absence of an exogenous source of this trace plasma 
protein. This is the first documentation of such a response with direct evidence 
that  the  protein  responsible  for  proteolytic activation  of Factor  X  is  indeed 
Factor VII/VIIa.  Evidence also  is provided that  this effector function can be 
induced  in  monocytes by  signals  from  appropriately  stimulated  T  cells.  The 
generation of factor VII or VIIa (VII/VIIa) represents a  further expansion of 
the  known  proteolytic repertoire of cells  of the  monocyte/macrophage series 
and has implications for the activation of the coagulation protease pathways in 
inflammatory lesions by lymphoid cells. 
Materials and Methods 
Cell Isolation and Culture.  Platelet-poor PBM were prepared from healthy donors from 
heparinized (5 U/ml) venous blood by centrifugation at 100 g for 20 rain. After removal 
of the platelet-rich plasma, the cells were washed once with incomplete medium (Leibov- 
itz's L-15 medium; Irvine Scientific, Santa Ana, CA) or RPMI-1640 (Gibco Laboratories, 
Grand Island, NY) prepared in pyrogen-free water containing 2 mM glutamine (Gibco) 
and 50 tzg/ml gentamycin (Schering Corp., Kenilworth, NJ) and recentrifuged at 100 g. 
All culture media and reagents were devoid of LPS contamination (<1  ng/mi) by the 
limulus amoebocyte lysate assay (E-toxate, Sigma Chemical Co., St. Louis, MO). 
PBM were isolated from either whole blood or platelet-poor blood cells by centrifuga- 
tion on Ficoll-Hypaque (Sigma Chemical Co., and Winthrop Laboratories, Menlo Park, 
CA, respectively) prepared in pyrogen-free water at a density of 1.074 g/ml) at 425 g for 
25 min at 17°C. The cells at the interphase were collected, washed twice with incomplete 
medium, and resuspended at 1 x  106 cells/ml in either serum-free medium or complete 
medium (the latter containing 10% heat-inactivated fetal calf serum). PBM contained <1 
platelet per mononuclear cell, <1% polymorphonuclear leukocytes, and >99% excluded 
trypan blue. 
Isolated monocytes and Leu-3a  ÷ lymphocytes were kindly isolated in our laboratory by 
Dr. Heikki Helin (7) and were prepared as follows:  monocytes were isolated from PBM 
by receptor-mediated adherence to plasma fibronectin on gelatin-coated surfaces (7, 25). 
1-ml aliquots containing  106 PBM in complete medium were incubated for 40 rain at 
37°C in  16-mm tissue culture wells (Costar, Cambridge, MA) coated with fibronectin by 
incubation with autologous plasma after coating the wells with gelatin. Nonadherent cells 
were removed 1 h later, and the adherent cells were washed twice with warm serum-free 
medium.  The  adherent  cells  were  >97%  positive  for  nonspecific  esterase  (26)  and 
represented 62.9 +  1.7% of the original esterase-positive cells.  Nonadherent cells were 
subjected to another cycle of adherence (overnight at 37°C) to deplete them of residual 
monocytes. After the  second cycle of adherence,  the  nonadherent  lymphocytes were 
incubated with a murine monoclonal antibody to Leu-3a, a cell surface epitope specific 
for a  helper/inducer subset  of human  T  cells (27).  Using fluorescein isothiocyanate- 
labeled F(ab)'2 fragments of goat anti-mouse Ig, the Leu-3a positive cells were collected 
after sorting  on a  FACS  II  or  FACS  IV  (Becton-Dickinson, Mountain  View,  CA)  as 
previously described (7). 
PBM at  1 ×  106/ml, were incubated in  12 ×  75 mm polypropylene tubes at 37°C in 
either complete medium for 18 h or serum-free medium for 5 h. In experiments to assess 
the potential role of culture medium in the responses, RPMI-1640 was replaced with L- 
15. Results were qualitatively comparable. Monocytes (~1  x  105) purified from 1 x  106 
PBM were cultured in polystyrene 16-mm plastic Costar plates, either alone or with 8.5 
x  105  Leu-3a  + T  cells  in  1 ml  of complete medium  for 4  h  at  37°C.  Bacterial LPS 1044  MONOCYTE  FACTOR  VII/VIIa ACTIVITY 
(Escherichia coli 0111:B4,  butanol-extracted) was added at final (optimal) concentrations 
of 10 #g/ml to cultures  in  complete medium and at  10  ng/ml to cultures  containing 
incomplete medium. 
Coagulation  Assays.  The  basal  procoagulant  activity (PCA)  of freshly  isolated (zero 
time) PBM was determined by immediately centrifuging 1 X 106 cells in  1 ml at 2,000 g 
for 15 min, discarding the supernatant and freezing the cell pellets at -70°C for assay of 
the total PCA. Cultured cells were handled in an identical manner at the termination of 
the incubation period. For total PCA assay the cell pellets were lysed in a final volume of 
0.33  ml  by  one  of two  methods:  either  repeated  freezing and  thawing  followed  by 
sonication as described previously (28), or by detergent lysis. The latter involved incubat- 
ing the cell pellets at 37°C in 0.1  ml of 150 mM NaC1 and 25 mM Hepes (Hepes saline) 
containing  15  mM octyl glucoside (Calbiochem-Behring Corp.,  La Jolla, CA). After  10 
rain, the volume was increased to 0.33 ml by the addition of Hepes saline and the samples 
were placed on ice. There was no effect of the detergent on assays of any of the coagulation 
proteases at the final concentration  in  the assays;  and maximal PCA was observed for 
incubation periods in octyl glucoside of 8-20 rain at 37°C.  For assay of viable cell PCA 
after culture of the PBM at 1 X 106 cells/ml, the cells were centrifuged at 2,000 g for 10 
rain in polypropylene tubes, resuspended in Hepes saline and the contents of two tubes 
pooled and adjusted to a final concentration of ! x  107 cells per milliliter in Hepes saline. 
PCA was quantitated by a one-stage clotting assay. Cell lysates or viable cells (0.05 mi) 
or thromboplastin standard (0.05 ml) was added to a  12 x  75 mm borosilicate tube that 
contained 0.05 ml of 20 mM CaCI~, and warmed to 37°C. After the addition of 0.05 ml 
of citrated platelet-poor normal plasma (diluted twofold in 20 mM citrate, 150 mM NaCI, 
pH 7.4),  the time required  for fibrin clot formation was visually recorded.  In selected 
experiments, normal human plasma was replaced with human plasmas genetically deficient 
in  specific coagulation  proteases (George King Biological  Co.,  Overland  Park,  KS)  to 
establish the entry point of the monocyte PCA into the coagulation protease sequence. 
Clotting times were converted to units of PCA from log-log plots of serial dilutions of a 
tissue  factor  standard  (rabbit  brain  thromboplastin;  Difco  Laboratories,  Detroit,  MI), 
which were assayed as previously described and for which 1,000 mU/ml samples gave 50 
+  2 s (28). 
Purified  Coagulation  Factors.  Factor  X  and  prothrombin  were  isolated  from  Cohn 
Fraction III (a gift from Dr. W. Brockway, Cutter Laboratories) as previously described 
(29).  Human fibrinogen was kindly provided by Dr.  E.  F.  Plow (Research Institute of 
Scripps Clinic).  Human Factor VII was prepared by the method of Broze and Majerus 
(30). Bovine Factor V was the generous gift of Drs. K. G. Mann and M. E. Nesheim (31). 
Chromogenic Assay for Factor X Activation.  Formation of activated Factor X  by rabbit 
brain thromboplastin or stimulated cell lysates was determined in a two-stage assay using 
the Factor Xa chromogenic substrate S-2222 (BZ-IIe-GIu-Gly-Arg-pNA)  (Kabi Diagnos- 
tica,  Stockholm,  Sweden).  In  the  first  stage of Factor  X  activation 0.2  ml of citrated 
normal or specific factor-deficient plasma (diluted 1:10 with 10 mM Tris, 150 mM NaCI, 
pH 7.4), 0.1  ml of tissue factor standard or cell lysate, and 0.008 mi of 0.5 M CaCI2 were 
incubated at 37°C.  After 3 min,  160 mU of hirudin  (Sigma Chemical Co.) in 0.6 ml of 
50 mM Tris, 227 mM NaCI, 10 mM EDTA, pH 8.3, was added to inactivate the thrombin 
generated in the first stage. After the addition of 0.1  ml of 2.7  mM S-2222, the initial 
rate of release of p-nitroaniline was monitored at 405 nm at 37 °C. p-Nitroaniline release 
was linear for at least 5 rain. 
Immunoglobulin  Fractions.  Rabbit  antibody  to  human  Factor  VII  was  prepared  by 
repeated  immunization  with  highly purified  Factor  VII in  complete,  then  incomplete 
adjuvant  (32).  An  IgG  fraction  of this  antibody  was  isolated  by  ammonium  sulfate 
precipitation (45% saturation) and chromatography on DEAE-cellulose (DE-52, Whatman) 
equilibrated with  15 mM phosphate (pH 8.0).  The specificity of this antibody has been 
extensively characterized and confirmed (32). Normal rabbit serum IgG was prepared in 
an identical manner. Goat antibody specific for human Factor VII was generously provided 
by Dr. S. Paul Bajaj (University of California, San Diego). TSAO  ET  AL.  1045 
Results 
Freshly isolated cells expressed basal  levels of total  cellular PCA  that  were 
quite low, e.g.  14 +__ 3 mU/106 cells. However, incubation of PBM for 5 h with 
LPS induced a 40-fold increase in total cellular PCA (567 ___ 200 mU/106 cells) 
over initial basal content or 30-fold relative to the unstimulated cultured PBM 
(19 _  3  mU/106 cells). Comparable increases were observed for intact, viable 
cells.  No  significant  differences in  PCA  generated  were  observed  for  cells 
incubated 5 h in serum-free medium as compared to 18 h in complete medium; 
and there was no significant recovery of PCA in the cell-free (100,000 g for 1 h) 
culture supernatants. The cellular PCA appeared to be predominantly of intra- 
cellular origin, since viable cells expressed only 5-20%  of the total functional 
activity, consistent with previous observations (6, 28). For assay of total PCA cell 
pellets were either disrupted by freeze-thaw and sonicated, or lysed in  15  mM 
octyl glucoside for 10  min at 37°C.  Detergent lysates contained 100-200%  of 
the PCA of that obtained by freeze-thaw and sonication. Therefore detergent 
lysis was used predominantly for these studies and key observations were con- 
firmed by freeze-thaw and sonication. Molecules responsible for PCA were not 
solubilized by the octyl glucoside, because activity present in the detergent lysate 
of LPS-stimulated PBM was distributed only in the residual cellular structures 
recovered by centrifugation at low force and vesicles recovered by centrifugation 
at  100,000  g  for  1  h.  Octyl  glucoside  solutions  added  to  plasma  to  a  final 
concentration of 20 mM, a 12-fold higher final concentration than in the adopted 
method, had no effect on function of the coagulation assays. 
To  characterize the molecular species of induced PCA,  cell lysates of LPS- 
stimulated PBM were assayed for acceleration of coagulation of various factor- 
deficient human plasmas in one-stage coagulation assays. As shown in Table I, 
plasmas deficient in Factors VIII or IX supported coagulation initiated by: (a) a 
TABLE  I 
Coagulation Factor Dependence of LPS-lnduced PCA in Human PBM 
Tissue factor*  LPS-stimulated  Control PBM 
PBM  *  plus Xa  t 
S  S  S 
Normal  44 _+ 611  46 -4- 4  36 4- 1 
Factor-deficient 
VII  47 4-5  40+_7  42+  1 
IX  54_  2  55 4- 4  51  4- 2 
Vll  166 +  14  76 4- 6  54 4- 5 
X  >200  >200  40 __. 1 
II  >200  >200  >200 
* Rabbit  brain  thromboplastin was  used  as a  source  of tissue  factor  and  was 
diluted to achieve a  PCA that was comparable to the PCA of LPS-stimulated 
PBM. Data of four separate experiments. 
* 1 X  106 PBM were cultured with 10 ng/ml LPS for 5 h  in serum-free medium 
(three experiments) or with 10 ttg/ml LPS in complete medium for 18 h  (six 
experiments). 
01  x  108  control cultured  PBM plus 0.56  ng/ml  of purified Factor  Xa (two 
experiments). 
! One-stage  clotting  time  is  expressed  as  the  mean  seconds  ___  the  standard 
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tissue factor source; (b) LPS-stimulated PBM, or (c) control PBM plus Factor Xa, 
as well as did control normal pooled plasma, indicating no requirement for these 
proteins  in  the  protease  pathway.  In  contrast,  LPS-stimulated  cells  did  not 
accelerate clotting of Factor X- or II-deficient plasmas and this was similar for 
the tissue factor source. Competence of the protease pathway was restored in 
Factor X-deficient plasma by repletion with purified Factor X, and in Factor 
II-deficient plasma by repletion with purified Factor II (data not shown). Tissue 
factor only slightly accelerated the coagulation of Factor VII-deficient plasma, 
i.e.,  from 220  s to  166 s (Table I).  However, the LPS-stimulated PBM lysates 
significantly accelerated coagulation of recalcified Factor VII-deficient plasma, 
i.e., from >200 s to 76 s, suggesting that these cells contained either legitimate 
Factor VII/VIIa or a protease with Factor VIIa-like activity. The cellular PCA 
was partially dependent on Factor VII because the rate of the response,  76 s, 
was less than that for normal control plasma,  46 s. These stimulated PBM did 
not initiate coagulation of Factor X-deficient plasma even though PBM  with 
added Xa directly induced coagulation. Thus the initiating activity in the absence 
of Factor VII  was dependent on  the presence of Factor X  and was a  Factor 
X-activating activity. The activities are synthesized de novo since all PCA activity 
was abolished by both actinomycin D and by cycloheximide (5). 
To obviate the possibility that the observed Factor VII-independent PCA was 
attributable to carryover of plasma Factor VII during cell isolation and to provide 
evidence that Factor VII is not produced constitutively by monocytes, the ability 
of these  control  cells  to  bind  exogenous  Factor  VII  and  to  accelerate  the 
coagulation of Factor  VII-deficient plasma  in  the presence of a  tissue factor 
source was quantitated. Iodinated Factor VII was added to and incubated with 
blood and  the cell population  before Ficoll-Hypaque separation.  The isolated 
PBM  cells were associated  with  <0.06%  of the total  label  added,  which was 
equivalent  to  <1  pg/106  monocytes, a  quantity  too  low  to  account  for  the 
observed Factor VII-like activity. As illustrated  in  Fig.  1,  the coagulation of 
Factor VII-deficient plasma by tissue factor was not accelerated by the addition 
of control cell lysates. This indicated that control cultured PBM did not possess 
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FIGURE  l.  LPS-stimulated human peripheral blood mononuclear cells express Factor VII- 
like procoagulant activity in a  dose-dependent manner. PBM cells were cultivated for 5 h  in 
serum-free medium in the presence (O) or absence (A) of I0 ng/ml LPS and disrupted by 
octyl glucoside.  Increasing concentrations of cellular lysates were tested for PCA activity in 
Factor  VII-deficient plasma.  The  LPS-stimulated  cells (which express  tissue  factor)  were 
assayed directly. The control unstimulated cells were assayed in the presence of 1,000 mU/ 
ml of tissue factor. The absence of effect in the latter is taken as evidence that there was not 
cellular carryover of Factor VII and that it was not produced by unstimulated cells. TSAO  ET  AL.  1047 
Factor VII, nor could they provide some otherwise inapparent substitute for the 
Factor  VII  requirement.  In  contrast,  LPS-stimulated  PBM  alone  expressed a 
Factor VII-independent PCA in a  dose-dependent manner as exhibited by the 
linear  PCA  response  with  increasing  cell  lysate.  Similar results have been  ob- 
served for all of the above experiments with intact viable cells, and cultivation 
of the  cells  in  the  presence or absence  of heat-inactivated  fetal calf serum  in 
either of two different media did not have a significant effect. 
Enzymatic Characterization.  The partial Factor VII independence of the cellu- 
lar PCA was quantitatively assayed in a  two-stage amidolytic assay using Factor 
X  as  substrate  for the cellular PCA  and  the chromogenic substrate  S-2222  to 
assay Factor Xa generation. LPS-stimulated PBM added to Factor VII-deficient 
plasma generated Factor Xa at a rate of 40% of that observed for normal human 
plasma substrate, whereas tissue factor was unable to generate Factor Xa activity 
(___10%) using either Factor VII- or X-deficient plasmas as substrate (Table II). 
The addition of purified Factor VII to Factor VII-deficient plasma quantitatively 
reconstituted the full capacity of the induced PCA to generate Factor Xa. The 
activity of LPS-stimulated  PBM was minimally expressed (<10%) in  Factor X- 
deficient plasma,  and  could be fully reconstituted by the  addition  of purified 
Factor  X.  In  contrast  to  tissue  factor,  LPS-stimulated  PBM  also were able  to 
generate  Factor  Xa  using  purified  Factor  X  in  the  absence of other proteins 
(Table II).  The generation of this  Factor Xa activity was  35%  of the maximal 
activity of that observed for an intact extrinsic pathway in the presence of normal 
plasma.  Thus, this represented the Factor X-activating protease alone without 
the  contribution  of cellular  tissue  factor;  and  indeed  the  rate  of Factor  Xa 
formation was  not  significantly different from that  observed  for  Factor  VII- 
deficient plasma. It should be noted that  these data  were highly reproducible 
whether the  monocyte  PCA  response  was  elicited  in  vitro  in  the  absence  or 
presence of heat-inactivated fetal calf serum and were not influenced by the type 
of culture medium used. 
TABLE  II 
Activation of Factor X by LPS-stimulated PBM* 
Plasma 
Tissue factor  ~  LPS-stimulated PBM  ! 
A4os/min  Percent  A4os/min  Percent 
Normal  0,054  100  0.060  100 
VII-def  0.005  9  0.024  40 
VII-clef + VII t  ND  ~  0.056  93 
X-def  0.006  10  0.005  9 
X-def + X**  ND  0.060  100 
Purified factor X**  0.002  4  0.021  35 
* Factor Xa generation was measured using the chromogenic substrate $2222, which is specific  for 
Factor Xa as described in Materials and Methods. 
* Rabbit brain thromboplastin diluted to give a clotting time of 48 s in normal human plasma. 
! 1 × 106 PBM incubated for 5 h at 37°C with 10 ng/ml of LPS in serum-free medium, The cell 
lysate had a clotting time of 47 s in normal plasma. 
! Factor VII at 0.5 #g/ml. 
Not determined. 
** Factor X at 6.5 #g/ml. 
Factor X at 6.5 gg/ml assayed in the absence of plasma and cell extract. 1048  MONOCYTE  FACTOR  VII/VIIa  ACTIVITY 
TABLE III 
Factors X and V Are Required by LPS-stimulated PBM  for Fibrin Formation in a System of 
Pur~ed Components* 
Clotting factors  Clotting time 
Fibrinogen  1I  Va*  X  Control PBM  LPS-stimulated 
(800 #g/ml)  (32 #g/ml)  (3.8 #g/ml)  (2.6 #g/ml)  +  Xa  !  PBM  ! 
s  s 
+  +  0  0  >240  >240 
+  +  +  0  19  >240 
+  +  +  +  ND  ~  31 
+  +  0  +  ND  111 
* Reaction mixtures (0.125 ml) were incubated at 37°C and contained 7.5 mM CaCI~. 
* 100 #g/ml of Factor V  was activated by thrombin, and the thrombin removed by ion exchange 
chromatography. 
g 1 x  106 PBM were incubated for 5 h at 37°C in serum-free medium. The cell pellet was solubilized 
in detergent and Factor Xa was added to 0.56 ng/ml. Clotting time in normal plasma, 36 s. 
! 1 x  10OPBM  were incubated with  10  ng/ml of LPS for 5  h  at  37°C in  serum-free medium. 
Clotting time in normal plasma, 38 s. 
Not determined. 
The ability of the induced cells to directly activate Factor X was demonstrated 
using a purified component assay that contained fibrinogen, prothrombin, Factor 
Va, and Factor X  (Table III). Control cell lysates failed to activate Factor X, as 
control PBM contained only 2% of the PCA expressed by LPS-stimulated cells 
(data not shown). LPS-stimulated PBM expressed minimal  PCA (>240 s) in the 
presence of fibrinogen, prothrombin,  Factor Va, and Ca  2÷. With the addition of 
Factor X, a profound acceleration (31 s) was observed with LPS-stimulated PBM, 
and  indicated  that  conversion  of Factor X  to  Factor Xa had  occurred.  In  the 
presence of Factor Va, acceleration of the coagulation rate was observed for the 
control cell  iysates plus purified  Factor Xa.  This  indicated that  Factor Va was 
absent from the control cells, but was required for maximal rates ofprothrombin 
generation  in  this  assay system.  Also,  in  the  absence  of added  Factor  Va  the 
activity of LPS-stimulated  PBM exhibited a  very limited capacity to accelerate 
the  coagulation  response,  i.e.,  a  time  of  111  s,  indicating  a  requirement  for 
Factor Va. 
Calcium  Requirements.  The  Factor  X-activating  PCA present  in  LPS-stimu- 
lated PBM cell lysates was entirely dependent upon available calcium ions. This 
was demonstrated  in a  two-stage assay. In the first stage,  LPS-stimulated  PBM 
were incubated with Factor X  in the absence or presence of Ca 2+ for 5 min at 
37°C. In the second stage, the other purified components and additional  CaCI2 
were added, and the time recorded for the appearance of fibrin. The results are 
given in Table IV.  With either  1.7 mM or 3.4 mM Ca  ~÷ present for Factor X 
activation during  the first stage, the PCA from LPS-stimulated PBM was com- 
parable  to  that  observed in  normal  human  plasma.  <10%  was observed with 
LPS-stimulated PBM, when Ca ~+ was omitted for Factor X activation during the 
first  stage.  This  minimal  expression  of  PCA  (<10%)  could  result  from  the 
activation  of Factor  X  during  the second stage of the assay that  contained  7.4 
mM CaC12. 
It has been demonstrated that both human  Factor VII and VIIa bind equiva- TSAO  ET  AL.  1049 
TABLE IV 
Calcium Requirement for Direct Factor X Activation by LPS-stimulated 
PBM* 
Ca  ~÷  Factor Va 
(raM)  (0.74 tzg/ml)  Clotting time  Total PCA 
s  mU/lO 6 PBM 
0  -  252 + 17  <0.5 
0  +  94 _+ 3  24 + 3 
1.7  +  52 -+ 2  280 + 46 
3.4  +  50 + 1  320 +_- 20 
* In the first stage, LPS-stimulated PBM were incubated for 5 min at 
37°C with Factor X at 8.6 t~g/ml in the absence or presence of the 
indicated concentrations of CaCI~ to allow for Factor X activation. After 
the addition of 32 t~g/ml prothrombin, 0.74 #g/ml Factor Va, 800 #g/ 
ml fibrinogen and additional CaCI~, the clotting time was recorded. The 
final concentration of CaCI2 in the second stage clotting assay was from 
7.4 to 8.8 raM. 
lently to  LPS-stimulated  monocytes, that  this binding  is  Ca  2+  dependent  (15), 
and  that  it presumably represents binding to tissue  factor (14).  To determine 
whether  the  association  of the  Factor  X-activating  protease  with  monocytes 
involved divalent ions,  PBM (1  ×  106/ml) were cultured for 5  h  in serum-free 
media in the absence or presence of LPS.  After culture the  intact viable cells 
were washed, incubated for 10 min at 37 °C in 1.0 ml of Hepes saline containing 
0-5 mM EDTA, and washed twice in Hepes saline before assay of the viable cell 
PCA. Whereas the EDTA wash had no effect on the viable cell PCA of control 
PBM, at  3.0-5.0  mM  EDTA the  LPS-stimulated  PCA  retained on intact cells 
was reduced by >80% (data not shown). The divalent ions involved appeared to 
be  tightly  bound,  because  1-2  mM  EDTA  only slightly  diminished  the  cell- 
bound PCA. The cell-associated Factor X-activating activity of LPS-stimulated 
PBM was dissociable in a manner similar to Factor VII. 
Immunochemical  Specificity.  To  determine  whether  the  Factor  X-activating 
molecule was indeed Factor VII or VIIa,  LPS-stimulated PBM were incubated 
with rabbit IgG containing neutralizing antibodies specific for human Factor VII 
(32).  It  was  first  necessary  to  verify  that  the  Factor  VII-specific  Ig  could 
neutralize  Factor VII  bound  to  LPS-stimulated  PBM.  After  5  h  of culture at 
37°C in serum-free media in the absence or presence of 10 ng/ml  LPS, viable 
PBM at 1-2 ×  106 cells/ml were resuspended in 0.2 ml of Hepes saline containing 
3 mM CaCi2 and 50 ng/ml of purified human Factor VII, and incubated for 20 
min at 4°C. After removal of non-cell associated Factor VII and treatment with 
normal or immune IgG, the PCA expressed by intact cells was quantitated. LPS- 
stimulated intact cells that were incubated with purified Factor VII accelerated 
the coagulation of both normal  and  Factor VII-deficient plasmas,  when com- 
pared with control cells (Table V). PCA in Factor VII-deficient plasma was 25- 
30% of that measured with normal plasma. This activity could be neutralized by 
anti-Factor VII IgG and not normal IgG. This was confirmed by a second anti- 
Factor VII IgG (kindly provided by Dr. Paul Bajaj). 
With  this  evidence for functional  neutralization  in  hand,  we  examined  the 
ability  to  neutralize  the  PCA  of  LPS-stimulated  PBM  that  were  devoid  of 1050  MONOCYTE  FACTOR  Vll/Vlla ACTIVITY 
TABLE  V 
Neutralization of PCA on LPS-stimulated PBM by Factor VII Specific 
Antibody 
Tissue*  Factor 
VII*  Ig° 
Viable cell PCA 
(mU/10  6 PBM) 
Factor VII- 
NHP  deficient 
plasma 
Control PBM  +  Normal  2.1  <l 
Control PBM  +  Anti-VII  2.0  <l 
LPS-PBM  +  Normal  50.0  13 
LPS-PBM  +  Anti-VII  3.5  <1 
LPS-PBM  0  Normal  27.0  9.9 
LPS-PBM  0  Anti-VII  3.0  <1 
* PBM at 1 x  106/ml were cultured for 5 h at 37°C in serum-free  medium in 
the absence or presence of l0 ng/ml of LPS. After incubation 2 X 106 PBM 
were collected by centrifugation and the cell pellets resuspended in 0.2 ml of 
Hepes saline containing 3 mM CaCI~. 
* Factor VII was added to the cell pellets at 50 ng/ml and the cells incubated 
for 20 min at 4 °C, washed twice, and resuspended  in 0.2 ml of Hepes saline 
containing  3 mM CaCI~. 
0 75 pg of rabbit anti Factor VII lgG or normal rabbit IgG was added to the 
cells. The cells were incubated for 30 rain at 37°C, washed twice, resuspended 
in Hepes  saline, and assayed for viable cell PCA in normal and Factor VII- 
deficient human plasma in one-stage clotting assays. 
NHP, normal human plasma. 
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FIGURE 2.  Neutralization of cellular Factor  VII/VIIa-like protease  activity in a dose-de- 
pendent fashion by IgG antibodies to human Factor VII/VIIa. Peripheral blood mononuclear 
cells (2 x  l0  B) were induced in serum-free culture with 10 ng/ml LPS, incubated for 30 rain 
at 37 °C with varying concentrations  of IgG antibodies to Factor VII (0) or 2.5 mg/ml normal 
IgG (X), and analyzed for residual Factor VII/VIIa-like PCA in Factor VII-deficient  plasma. 
exogenous purified  Factor  VII.  This  was  neutralized also  by  the  Factor  VII 
antibody  (Table  V).  When  this  was  examined  in  a  quantitative  titration  of 
antibody, a  dose-dependent neutralization of cellular Factor VII/VIIa-like  pro- 
tease activity was observed (Fig.  2). This was true for two independent sources 
of antibodies to highly purified Factor VII. Thus, the Factor VII/VIIa-like  PCA TSAO  ET  AL.  1051 
of LPS-stimulated PBM was immunochemically identified as human Factor VII 
or its activated derivative, Factor VIIa. 
T Cell Requirement.  Previous studies in our laboratory have established that 
the  cellular  source  of the  LPS-induced tissue  factor-like  PCA  expressed  by 
human PBM is the monocyte. However, the expression of this monocyte PCA 
after exposure to  LPS has appeared to be dependent upon the presence of T 
lymphocytes (5, 7) when the monocytes are isolated without activation. Because 
no information was available regarding the cellular pathways for induction of 
monocyte Factor  VII/VIIa,  the  T  cell  requirement has  been  characterized. 
Peripheral blood monocytes were purified by adherence to plasma fibronectin 
on gelatin-coated plastic surfaces to a  relative purity of >97%,  as indicated by 
nonspecific esterase staining.  A  T  lymphocyte inducer/helper population  was 
isolated from nonadherent lymphocytes by fluorescence-activated cell sorting 
with monoclonal antibody Leu-3a followed by fluoresceinated F(ab)'2 fragments 
of goat anti-mouse Ig. Reconstituted cells (Leu-3a  ÷ T  cells plus monocytes at an 
8:1  ratio) responded with a 20-fold increase in PCA relative to monocytes alone 
(270 vs.  13 mU/106 PBM) after LPS stimulation. Therefore, a  Leu-3a  ÷ T  cell 
population was required for the LPS induction of this monocyte PCA. Similarly 
to LPS-stimulated whole PBM, the PCA of the T  cell-monocyte mixture in one- 
stage clotting assays was partially dependent on Factor VII and entirely depend- 
ent on Factor X. 
When assayed in normal human plasma in the two-stage amidolytic assay, the 
LPS-stimulated reconstituted cultures of purified T  Leu-3a  ÷ lymphocytes and 
monocytes generated five times more Factor Xa-dependent activity than did 
monocytes alone (Table VI). In the absence of T  cells nearly all of the amidolytic 
activity (91%) expressed by LPS-exposed monocytes was independent of Factor 
VII.  In the presence of LPS-stimulated Leu-3a  ÷ T  cells, monocytes expressed 
TABLE  VI 
Activation of Factor X by Monocytes Requires T Cell Collaboration* 
Plasma 
LPS-Ti.d-Mo  ~  LPS-Mo  ! 
A4o~/min  Percent  A4os/min  Percent 
Normal  0.049  100  0.011  100 
VII-def  0.019  39  0.010  91 
VII-def +  VII  I  0.048  98  ND  ~  -- 
X-def  0.010  20  0.005  45 
X-def  +  X**  0.047  96  ND  -- 
X ~  0.002  4  ND  -- 
* Factor Xa  generation was measured using the chromogenic substrate S-2222  as described in 
Materials and Methods. 
* Monocytes (Mo)  purified by adherence from 1 X 105 PBM were reconstituted with 8.5 ×  105 Leu- 
3a  + helper/inducer T cells (Ti,a)  and cultured for 4 h at 37 °C in complete medium in the presence 
of 10 #g/ml LPS. Clotting time in normal plasma, 57 s. 
0 Monocytes, purified by adherence from 1 X 10  a PBM, were cultured for 4 h at 37°C in complete 
medium in the presence of 10 #g/ml LPS. Clotting time in normal plasma, 122 s. 
I Factor VII at 0.5 #g/ml. 
Not determined. 
** Factor X at 6.5 #g/ml. 
Factor X at 6.5 #g/ml assayed in the absence of plasma. 1052  MONOCYTE  FACTOR  VII/VIIa ACTIVITY 
39%  of the activity  of normal  human plasma  when assayed  in  Factor  VII- 
deficient plasma, and 20%  of the activity when assayed in Factor X-deficient 
plasma.  These activities were  fully restored  to  the  level  observed in  normal 
plasma by repletion with each of the purified coagulation proteins. The amount 
of the Factor VII-independent PCA expressed by the reconstituted cells (39%, 
Table VI) was similar to that of LPS-stimulated PBM (40%, Table II). In addition, 
the PCA of the reconstituted cells could be neutralized by antibodies to Factor 
VII in a  dose-dependent fashion (data not shown). Therefore, LPS-stimulated 
monocytes in the presence of Leu-3a  + T  inducer/helper lymphocytes expressed 
a Factor VII-independent PCA that was comparable in all respects to the PCA 
of LPS-stimulated PBM. 
Discussion 
One of the major pathways of the immune response involves T cell-instructed 
responses by cells of the monocyte/macrophage series. One of the effector limbs 
of this pathway culminates in thrombin formation and local fibrin deposition in 
immunologic lesions as demonstrated by Dvorak, Colvin, and colleagues (33-36) 
for  delayed cutaneous hypersensitivity. Implication of this pathway has  been 
further substantiated by the attenuating effects of anticoagulation (37).  Neutral 
proteases are synthesized by monocytes and macrophages under the influence of 
T cells and their products (38, 39). These properties are well within the currently 
recognized repertoire of responses of these effector cells and appear central not 
only to their role in immunologically mediated inflammation but as well to the 
initiation of intravascular coagulation (40, 41). 
Monocytes,  the  early  migratory  cells  of this  lineage,  are  noteworthy  for 
vigorous T cell-dependent responses to a variety of biologically relevant stimuli, 
including responses that initiate the coagulation protease network (1-4, 24, 37, 
38,  42,  43).  Whereas  many  of the  proteolytic  responses of the  monocyte/ 
macrophage are direct, namely secretion of an active protease, the recruitment 
of the coagulation protease network has until recently been thought to involve 
only the synthesis and cell surface expression of tissue factor, a  nonenzymatic 
cofactor that binds Factor VII and VIIa, and enhances their functional activity 
(14-16, 44). Recently, two additional roles of the monocyte have been described. 
First, monocytes can assemble the second macromolecular complex in the extrin- 
sic pathway, the prothrombinase complex, which is composed of Factor Xa and 
Va and which functions to proteolytically activate prothrombin (45).  Indeed, 
monocytes contain significant quantities of the requisite cofactor, i.e., Factor V 
(45).  This  series  of molecular assemblies is  essential  for  propagation  of the 
extrinsic  coagulation pathway.  Second, when properly instructed by  T  cells, 
monocytes can  synthesize and  express a  functional prothrombinase that  is  a 
membrane-associated serine  protease  unrelated  to  other  known  coagulation 
proteases (18, 19). This latter protease represents primary initiation rather than 
propagation, but is distinct from the molecular biology of the response charac- 
terized here. 
In the present study we provide substantial evidence that participation of the 
monocyte in the extrinsic coagulation pathway is more complex than originally 
suspected. It not only synthesizes tissue factor but also can produce Factor VII/ TSAO  ET  AL.  1053 
VIIa and assemble it on the cell surface in a  functional form. Whether this is 
single  chain  zymogen  VII  or  two  chain-activated  VIIa  is  not  known  but  is 
currently under analysis. However, both forms are active (16) when bound to 
tissue factor via calcium ions (14, 44). We assume that the Factor VII/VIIa may 
be associated  with  tissue  factor on  the  cell  surface,  though  this  will  require 
specific analysis. 
Others  have described  cellular  Factor  X-activating activity in  a  variety of 
neoplastic and non-neoplastic cells (20-23).  Such proteolytic activity could rep- 
resent Factor VII/VIIa;  however, Gordon and Gross (20) have demonstrated 
that the activity from rabbit lung carcinoma cells was a  cysteine protease, thus 
not Factor VII/VIIa. The evidence from studies of rabbit (21) and murine (23) 
macrophages suggests the possibility of Factor VIIa-like activity, but these studies 
did not establish  whether the responsible molecules were indeed Factor VII/ 
VIIa. Other observations, such as those with human allogeneic lymphocyte (42) 
or IgG-induced (43) responses, suggested the possibility of procoagulant activity 
in addition to tissue factor; however, the identity of such additional activity was 
not delineated. 
Support for the production and expression of Factor VII/VIIa by LPS-induced 
T  cell-instructed monocytes was derived from several lines of evidence. Enzy- 
matic activity of the cell-associated procoagulant activity directly cleaved Factor 
X  as demonstrated in both coagulation and amidolytic assays.  The proteolytic 
response  was calcium dependent,  as would be expected for a  3,-carboxylated 
protease  of the  coagulation  pathway,  and  it  was  abolished  by  monospecific 
antibodies to Factor VII/VIIa.  In addition, the Factor VII/VIIa was bound to 
the cell surface by a tight calcium adduct, since relatively high concentrations of 
EDTA were necessary to dissociate the protease from the intact viable procoag- 
ulant active monocyte. Synthesis of Factor VII/VIIa was not constitutive since 
there was no functional activity in unstimulated intact or disrupted cells, even 
when an exogenous source of tissue factor was provided. As for the induction of 
tissue factor (7), T  cells of the Leu-3a positive helper/inducer subclass have been 
implicated in the collaborative induction of Factor VII/VIIa in monocytes when 
properly isolated in a basal state. Whether the induction of Factor VII/VIIa is 
mediated by precisely the same signals from the T  cell that induce tissue factor 
is unknown. Indeed, until the communicative requirements are delineated at the 
molecular level  it  will  be  difficult to  determine whether the  linkage  of the 
induction of tissue factor and Factor VII/VIIa is a  function that is intrinsic to 
the monocyte/macrophage, or elective and at the discretion of the T  cell. 
The present observations further expand on the hypothesis that cells of the 
monocyte/macrophage lineage are intimately involved in initiation of the coag- 
ulation protease network. The functional necessity for the cellular synthesis of 
the proteins of the extrinsic cascade might seem less than obvious in view of the 
availability of these  zymogens in  plasma  and  body  fluids.  However,  the  low 
concentrations of many of these may preclude effective assembly of the extrinsic 
pathway  in  extravascular  sites.  However,  cellular  synthesis  could  provide  a 
greater  efficiency of assembly  into  proteolytically functional  complexes  and 
would contribute the advantage of coordinate synthesis and cell surface expres- 1054  MONOCYTE  FACTOR  VII/VIIa  ACTIVITY 
sion of multiple molecules of the extrinsic pathway. The preservation of such 
complex pathways of signals for induction suggests that they may be significant. 
Summary 
In the present study we demonstrate that human monocytes can be induced 
by the model stimulus, lipopolysaccharide (LPS),  to produce and assemble on 
their  surface functional  Factor  VII/VIIa.  This  protease  was  not  induced in 
relatively purified monocytes alone following exposure to LPS; but was induced 
in the presence of Leu-3a positive helper/inducer T  cells. The Factor VII/VIIa 
protease activity represented 35-40%  of the potential initiating activity for the 
extrinsic coagulation pathway and was demonstrated using functional coagulation 
assays, as well as in amidolytic assays for the activation of Factor X. This activity 
of cell-bound Factor VII/VIIa appeared to involve a  tight adduct of calcium. 
The identity of the Factor X-activating protease as Factor VII/VIIa was con- 
firmed by the capacity of antibody specific for Factor VII/VIIa to neutralize the 
cell-bound protease.  Further  propagation  of the  extrinsic  pathway  following 
generation of Factor Xa required addition of exogenous Factor Va. 
These results expand the repertoire of proteases that  have been identified 
with  appropriately  triggered  cells  of the  monocyte/macrophage series,  and 
suggest  that  initiation  and  propagation  of the  extrinsic  coagulation  protease 
network on  induced monocytes involves not only expression of the initiating 
cofactor  molecule,  tissue  factor,  but  also  production  of Factor  VII  and  its 
organization into the molecular assembly. Thus,  in the absence of exogenous 
Factor VII/VIIa a  directly proteolytic effector cell can be generated. Further 
molecular assembly of the extrinsic pathway on the monocyte surface sequentially 
expands the proteolytic capacity of this response. The synthesis and assembly of 
the extrinsic activation complex by the monocyte and its derived progeny, the 
macrophage, provides a  mechanism by which coagulation is initiated under T 
cell instruction at sites of immunologic responses. 
The authors readily acknowledge the excellent technical assistance by Sheri Young and 
David Revak as well as preparation of the manuscript by Ellen Schmeding. 
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